The purpose of this study is to assess the safety and performance of the 23mm Portico
Transcatheter Heart Valve and the TAVI Transapical Delivery System in subjects with severe
symptomatic aortic stenosis
Device: Portico Transapical Aortic Valve System
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01742598
Ages eligible for Study
65 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Subject has signed the study Informed Consent Form and Data Protection Form prior to participating in the study.
Subject is 65 years of age or older at the time of index procedure, and/or has comorbidities that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude surgical valve replacement.
Subject's aortic annulus is 19-21mm diameter as measured by echocardiography (echo) or CT conducted within 90 days prior to the index procedure.
Subject has senile degenerative aortic stenosis with echocardiography derived mean gradient greater than (>) 40mmHg or jet velocity greater than 4.0 m/s or an initial valve area of less than (<) 0.8 cm2 (or aortic valve area index less than or equal to
(≤) 0.6 cm2/m2). (Baseline measurement taken by echo within 90 days of index procedure).
Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV.
Subject is deemed high operable risk and suitable for TAVI per the medical opinion of the Subject Selection Committee.
Subject's predicted operative mortality or serious, irreversible morbidity risk is less than (<) 50% at 30 days post index procedure.
Subject is unwilling or unable to comply with all study-required follow-up evaluations.
Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to (≤) 180 days) prior to the index procedure.
Subject has a chest condition than prevents transapical access.
Subject has carotid artery disease requiring intervention.
Subject has documented evidence of a myocardial infarction (MI) within 6 months (less than or equal to (≤) 180 days) prior to the index procedure.
Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
Subject has mitral valvular regurgitation greater than (>) grade III.
Subject has moderate or severe mitral stenosis.
Subject has aortic root angulation greater than (>) 70 degrees (horizontal aorta).
The distance from the left ventricular apex to the aortic annulus is less than (<) 45mm (4.5cm).
Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
Subject refuses any blood product transfusion.
Subject refuses surgical valve replacement.
Subject has left ventricular ejection fraction (LVEF) less than (<) 20%.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.